Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YRHDV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD22-NMS249
|
|||||
| Synonyms |
Anti-CD22 NMS249; Anti CD22 NMS249
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
Follicular lymphoma [ICD11:2A80]
Investigative
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Pinatuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PAB-DEA
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB, HC A114C).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.